On 12 June 2019 the Canadian Agency for Drugs and Technologies in Health (CADTH) reported changes (which came into effect on 1 July 2019) to transition Cancer Drug Implementation Advisory Committee functions to the CADTH pan-Canadian Oncology Drug Review review process. The changes aim to:
- "enhance the transparency of the pan-Canadian cancer drug review process";
- "allow for greater stakeholder input into the development of a provisional algorithm for each new cancer drug or indication to indicate how the new therapy could be used compared to existing funded treatments; and to indicate the impact on the sequence of use for other existing funded therapies to better support jurisdictional decision-making for drug reimbursement"; and
- "streamline and reduce the duplication of administrative processes".
The reported changes follow a period (beginning March 2019) of consultation with stakeholders.
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.
